{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:52:49Z","timestamp":1783655569860,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e0 degli studi \"Magna Graecia\" di Catanzaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40263-025-01166-8","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:59:19Z","timestamp":1740682759000},"page":"513-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the Effectiveness of Adjunctive Cenobamate in Focal Epilepsy: A Time-Based Analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"Roberta","family":"Roberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"D\u2019Aniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Di Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Fronzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Pascarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Sammarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-8123","authenticated-orcid":false,"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"1166_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE Official Report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475\u201382.","journal-title":"Epilepsia"},{"key":"1166_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(23)01048-6","volume":"402","author":"AA Asadi-Pooya","year":"2023","unstructured":"Asadi-Pooya AA, Brigo F, Lattanzi S, Blumcke I. Adult epilepsy. Lancet. 2023;402:412\u201324.","journal-title":"Lancet"},{"key":"1166_CR3","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","volume":"5","author":"G Deuschl","year":"2020","unstructured":"Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5:e551\u201367.","journal-title":"Lancet Public Health"},{"key":"1166_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","volume":"22","author":"E Perucca","year":"2023","unstructured":"Perucca E, Perucca P, White HS, Wirrell EC. Drug resistance in epilepsy. Lancet Neurol. 2023;22:723\u201334.","journal-title":"Lancet Neurol"},{"key":"1166_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.674483","author":"A Fattorusso","year":"2021","unstructured":"Fattorusso A, Matricardi S, Mencaroni E, Dell\u2019Isola GB, Di Cara G, Striano P, et al. The pharmacoresistant epilepsy: an overview on existant and new emerging therapies. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2021.674483.","journal-title":"Front Neurol"},{"key":"1166_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jamaneurol.2022.2635","volume":"79","author":"C Steriade","year":"2022","unstructured":"Steriade C, French J. Tackling the unmet therapeutic needs in nonsurgical treatments for epilepsy. JAMA Neurol. 2022;79:1223.","journal-title":"JAMA Neurol"},{"key":"1166_CR7","unstructured":"FDA. XCOPRI. Prescribing information. [Internet]. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212839s000lbl.pdf. Accessed 10 Dec 2024."},{"key":"1166_CR8","unstructured":"EMA. ONTOZRY. Summary of product characteristics. [Internet]. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ontozry-epar-product-information_en.pdf. Accessed 10 Dec 2024."},{"key":"1166_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug\u2013drug interactions and tolerability. CNS Drugs. 2021;35:609\u201318.","journal-title":"CNS Drugs"},{"key":"1166_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009530","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.0000000000009530.","journal-title":"Neurology"},{"key":"1166_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol"},{"key":"1166_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61:1099\u2013108.","journal-title":"Epilepsia"},{"key":"1166_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200792","author":"P Klein","year":"2022","unstructured":"Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022. https:\/\/doi.org\/10.1212\/WNL.0000000000200792.","journal-title":"Neurology"},{"key":"1166_CR14","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/epi.17007","volume":"62","author":"JA French","year":"2021","unstructured":"French JA, Chung SS, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62:2142\u201350.","journal-title":"Epilepsia"},{"key":"1166_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/epi4.12239","volume":"3","author":"E Perucca","year":"2018","unstructured":"Perucca E. From clinical trials of antiepileptic drugs to treatment. Epilepsia Open. 2018;3:220\u201330.","journal-title":"Epilepsia Open."},{"key":"1166_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/epi.16476","volume":"61","author":"S Thieffry","year":"2020","unstructured":"Thieffry S, Klein P, Baulac M, Plumb J, Pelgrims B, Steeves S, et al. Understanding the challenge of comparative effectiveness research in focal epilepsy: a review of network meta-analyses and real-world evidence on antiepileptic drugs. Epilepsia. 2020;61:595\u2013609.","journal-title":"Epilepsia"},{"key":"1166_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/nep.13742","volume":"25","author":"JR Bosdriesz","year":"2020","unstructured":"Bosdriesz JR, Stel VS, van Diepen M, Meuleman Y, Dekker FW, Zoccali C, et al. Evidence-based medicine\u2014when observational studies are better than randomized controlled trials. Nephrology. 2020;25:737\u201343.","journal-title":"Nephrology"},{"key":"1166_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16321","author":"PJ Karoly","year":"2019","unstructured":"Karoly PJ, Romero J, Cook MJ, Freestone DR, Goldenholz DM. When can we trust responders? Serious concerns when using 50% response rate to assess clinical trials. Epilepsia. 2019. https:\/\/doi.org\/10.1111\/epi.16321.","journal-title":"Epilepsia"},{"key":"1166_CR19","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/epi.17621","volume":"64","author":"WT Kerr","year":"2023","unstructured":"Kerr WT, Auvin S, Van der Geyten S, Kenney C, Novak G, Fountain NB, et al. Time-to-event clinical trial designs: existing evidence and remaining concerns. Epilepsia. 2023;64:1699\u2013708.","journal-title":"Epilepsia"},{"key":"1166_CR20","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1111\/epi.18091","volume":"65","author":"R Roberti","year":"2024","unstructured":"Roberti R, Assenza G, Bisulli F, Boero G, Canafoglia L, Chiesa V, et al. Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program. Epilepsia. 2024;65:2909\u201322.","journal-title":"Epilepsia"},{"key":"1166_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522\u201330.","journal-title":"Epilepsia"},{"key":"1166_CR22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"},{"key":"1166_CR23","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1212\/WNL.0000000000001585","volume":"84","author":"JA French","year":"2015","unstructured":"French JA, Gil-Nagel A, Malerba S, Kramer L, Kumar D, Bagiella E. Time to prerandomization monthly seizure count in perampanel trials. Neurology. 2015;84:2014\u201320.","journal-title":"Neurology"},{"key":"1166_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(23)00202-8","volume":"22","author":"JA French","year":"2023","unstructured":"French JA, Friedman D. Appropriate selection of participants for clinical trials in epilepsy. Lancet Neurol. 2023;22:554\u20135.","journal-title":"Lancet Neurol"},{"key":"1166_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17568","author":"WT Kerr","year":"2023","unstructured":"Kerr WT, Chen H, Figuera Losada M, Cheng C, Liu T, French J. Reasons for ineligibility for clinical trials of patients with medication-resistant epilepsy. Epilepsia. 2023. https:\/\/doi.org\/10.1111\/epi.17568.","journal-title":"Epilepsia"},{"key":"1166_CR26","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40263-020-00759-9","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M, et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020;34:1105\u201320.","journal-title":"CNS Drugs"},{"key":"1166_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106592","volume":"172","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Nisman A, Ferrari L. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study. Epilepsy Res. 2021;172: 106592.","journal-title":"Epilepsy Res"},{"key":"1166_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","volume":"112","author":"KL Makridis","year":"2023","unstructured":"Makridis KL, Kaindl AM. Real-world experience with cenobamate: a systematic review and meta-analysis. Seizure Eur J Epilepsy. 2023;112:1\u201310.","journal-title":"Seizure Eur J Epilepsy"},{"key":"1166_CR29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"P Kwan","year":"2010","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug-resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on therapeutic strategies. Epilepsia [Internet]. 2010;51:1069\u201377. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x.","journal-title":"Epilepsia [Internet]"},{"key":"1166_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108239","volume":"123","author":"S Auvin","year":"2021","unstructured":"Auvin S, Damera V, Martin M, Holland R, Simontacchi K, Saich A. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome. Epilepsy Behav. 2021;123: 108239.","journal-title":"Epilepsy Behav"},{"key":"1166_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/dmcn.15187","volume":"64","author":"SR Cohen","year":"2022","unstructured":"Cohen SR, Helbig I, Kaufman MC, Schust Myers L, Conway L, Helbig KL. Caregiver assessment of quality of life in individuals with genetic developmental and epileptic encephalopathies. Dev Med Child Neurol. 2022;64:957\u201364.","journal-title":"Dev Med Child Neurol"},{"key":"1166_CR32","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s40120-023-00510-8","volume":"12","author":"A Pinsent","year":"2023","unstructured":"Pinsent A, Weston G, Adams EJ, Linley W, Hawkins N, Schwenkglenks M, et al. Determining the relationship between seizure-free days and other predictors of quality of life in patients with Dravet syndrome and their carers from FFA registration studies. Neurol Ther. 2023;12:1593\u2013606.","journal-title":"Neurol Ther."},{"key":"1166_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.P1.5-032","author":"M Kamin","year":"2019","unstructured":"Kamin M, Ferrari L. Time to onset of efficacy in seizure reduction with cenobamate (YKP3089) in patients with uncontrolled partial seizures from 2 randomized clinical trials (P1.5\u2013032). Neurology. 2019. https:\/\/doi.org\/10.1212\/WNL.92.15_supplement.P1.5-032.","journal-title":"Neurology"},{"key":"1166_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","volume":"96","author":"C Brandt","year":"2022","unstructured":"Brandt C, S\u00e1nchez-\u00c1lvarez JC, Steinhoff BJ, Milanov I, Serratosa JM. Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86\u201393.","journal-title":"Seizure"},{"key":"1166_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1239152","author":"N Pietrafusa","year":"2023","unstructured":"Pietrafusa N, Falcicchio G, Russo E, Lattanzi S, Goffredo B, Simeoli R, et al. Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence? Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1239152.","journal-title":"Front Pharmacol"},{"key":"1166_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17515","author":"S Elakkary","year":"2023","unstructured":"Elakkary S, Hagemann A, Klimpel D, Bien CG, Brandt C. A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam. Epilepsia. 2023. https:\/\/doi.org\/10.1111\/epi.17515.","journal-title":"Epilepsia"},{"key":"1166_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109156","volume":"142","author":"M Osborn","year":"2023","unstructured":"Osborn M, Abou-Khalil B. The cenobamate-clobazam interaction\u2014evidence of synergy in addition to pharmacokinetic interaction. Epilepsy Behav. 2023;142: 109156.","journal-title":"Epilepsy Behav"},{"key":"1166_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/epi.17843","volume":"65","author":"R Roberti","year":"2024","unstructured":"Roberti R, Di Gennaro G, Anzellotti F, Arnaldi D, Belcastro V, Beretta S, et al. A real-world comparison among third-generation antiseizure medications: results from the COMPARE study. Epilepsia. 2024;65:456\u201372.","journal-title":"Epilepsia"},{"key":"1166_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792\u2013802.","journal-title":"Lancet Neurol"},{"key":"1166_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1369384","author":"S Chen","year":"2024","unstructured":"Chen S, Fang W, Zhao L, Xu H. Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1369384.","journal-title":"Front Pharmacol"},{"key":"1166_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","volume":"111","author":"\u00c1 Beltr\u00e1n-Corbellini","year":"2023","unstructured":"Beltr\u00e1n-Corbellini \u00c1, Romeral-Jim\u00e9nez M, Mayo P, S\u00e1nchez-Miranda Rom\u00e1n I, Iruzubieta P, Chico-Garc\u00eda JL, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure Euro J Epilepsy. 2023;111:71\u20137.","journal-title":"Seizure Euro J Epilepsy"},{"key":"1166_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107242","volume":"197","author":"DA Becker","year":"2023","unstructured":"Becker DA, Demko SA. Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review. Epilepsy Res. 2023;197: 107242.","journal-title":"Epilepsy Res"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01166-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01166-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01166-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:17:27Z","timestamp":1744219047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01166-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01166-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"2 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.R., E. Russo, and S.L. contributed to the study conception and design. Data collection was performed by V.C., A.D.A., C.D.B., Giancarlo D.G., F.F., E.F., A.M., A.P. E. Rosati, and I.S.; data analysis was performed by R.R. and Gianfranco D.G. The first draft of the manuscript was written by R.R., Gianfranco D.G., E. Russo, and S.L. and all authors commented on previous versions of the manuscript. All authors read and approved of the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Open access funding provided by Universit\u00e0 degli studi \"Magna Graecia\" di Catanzaro within the CRUI-CARE Agreement. Open Access fee was funded by University Magna Grecia of Catanzaro. This research was supported by an unconditional grant from Angelini Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"R.R. has received consultancy fees from Eisai. A.D. has participated in pharmaceutical industry-sponsored clinical trials for UCB Pharma, has received speaker honoraria from Eisai, UCB, Angelini Pharma, and Neuraxpharm, and has served on advisory boards for Angelini Pharma. C.D.B. has received consulting fees and honoraria from GW Pharmaceuticals, UCB Pharma, Eisai, Angelini Pharma, and Bial outside the submitted work. Giancarlo D.G. has participated on advisory boards and pharmaceutical industry-sponsored symposia for UCB Pharma, Eisai, BIAL, Lusofarmaco, LivaNova, Arvelle, and Angelini Pharma. E. Rosati has received consultancy fees from Angelini, UCB, Jazz Ph, Ecupharma, and Eisai. E. Russo has received speaker fees or funding from and has participated in advisory boards for Arvelle Therapeutics, Angelini Pharma, Eisai, Pfizer, GW Pharmaceuticals, Jazz Pharmaceuticals, UCB, and Lundbeck. S.L. has received speaker\u2019s or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, Medscape, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, and GW Pharmaceuticals outside the submitted work. S.L. received research grant support from the Ministry of Health and the Ministry of University and Research outside the submitted work. The remaining authors have no conflicts of interest. S.L. is an Editorial Board member of CNS Drugs. S.L. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The overall, anonymized data collection was approved by the Ethics Committee of Calabria Region, Italy (protocol number 416\/20) and conducted in accordance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All patients provided written informed consent to participate in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}